Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 5
2022 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma.
Isberner N, Gesierich A, Balakirouchenane D, Schilling B, Aghai-Trommeschlaeger F, Zimmermann S, Kurlbaum M, Puszkiel A, Blanchet B, Klinker H, Scherf-Clavel O. Isberner N, et al. Among authors: zimmermann s. Cancers (Basel). 2022 Sep 20;14(19):4566. doi: 10.3390/cancers14194566. Cancers (Basel). 2022. PMID: 36230489 Free PMC article.
A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients.
Gerner B, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Zimmermann S, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O. Gerner B, et al. Among authors: zimmermann s. Pharmaceutics. 2022 Nov 22;14(12):2556. doi: 10.3390/pharmaceutics14122556. Pharmaceutics. 2022. PMID: 36559050 Free PMC article.
Development and validation of a bioanalytical method for the quantification of axitinib from plasma and capillary blood using volumetric absorptive microsampling (VAMS) and on-line solid phase extraction (SPE) LC-MS.
Opitz P, Zimmermann S, Mc Laughlin AM, Müller L, Fuxius S, Illerhaus G, Scherf-Clavel O, Kloft C, Hempel G; ON-TARGET study consortium. Opitz P, et al. Among authors: zimmermann s. J Pharm Biomed Anal. 2022 Nov 30;221:115033. doi: 10.1016/j.jpba.2022.115033. Epub 2022 Sep 8. J Pharm Biomed Anal. 2022. PMID: 36148722
Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum - Application to therapeutic drug monitoring.
Aghai-Trommeschlaeger F, Zimmermann S, Gesierich A, Kalogirou C, Goebeler ME, Jung P, Pelzer T, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O. Aghai-Trommeschlaeger F, et al. Among authors: zimmermann s. Clin Biochem. 2022 Jul-Aug;105-106:35-43. doi: 10.1016/j.clinbiochem.2022.04.011. Epub 2022 Apr 26. Clin Biochem. 2022. PMID: 35483452
Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib.
Zimmermann S, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Gesierich A, Schilling B, Kalogirou C, Goebeler ME, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O. Zimmermann S, et al. J Pharm Biomed Anal. 2023 May 10;228:115311. doi: 10.1016/j.jpba.2023.115311. Epub 2023 Feb 23. J Pharm Biomed Anal. 2023. PMID: 36841066
Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial.
Isberner N, Kraus S, Grigoleit GU, Aghai F, Kurlbaum M, Zimmermann S, Klinker H, Scherf-Clavel O. Isberner N, et al. Among authors: zimmermann s. Cancer Chemother Pharmacol. 2021 Dec;88(6):973-983. doi: 10.1007/s00280-021-04351-w. Epub 2021 Sep 10. Cancer Chemother Pharmacol. 2021. PMID: 34505930 Free PMC article. Clinical Trial.
Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.
Mc Laughlin AM, Schmulenson E, Teplytska O, Zimmermann S, Opitz P, Groenland SL, Huitema ADR, Steeghs N, Müller L, Fuxius S, Illerhaus G, Joerger M, Mayer F, Fuhr U, Holdenrieder S, Hempel G, Scherf-Clavel O, Jaehde U, Kloft C, For The On-Target Study Consortium. Mc Laughlin AM, et al. Among authors: zimmermann s. Cancers (Basel). 2021 Dec 14;13(24):6281. doi: 10.3390/cancers13246281. Cancers (Basel). 2021. PMID: 34944899 Free PMC article.
12 results